Obesity and its impact on transplantation and alloimmunity

Transplantation

Volumn 96, Issue 1, 2013, Pages 10-16

  Heinbokel, Timm ^a,b   Floerchinger, Bernhard ^c   Schmiderer, Andreas ^d   Edtinger, Karoline ^a   Liu, Guangxiang ^a   Elkhal, Abdallah ^a   Tullius, Stefan G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Alloimmunity; Obesity; Transplantation outcome

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; LEPTIN;

ADIPOSE TISSUE; ALLOIMMUNITY; ANTIGEN RECOGNITION; BARIATRIC SURGERY; CARDIAC GRAFT REJECTION; DISEASE ASSOCIATION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; NONHUMAN; OBESITY; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PATHOPHYSIOLOGY; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK BENEFIT ANALYSIS; SURGICAL INFECTION; WEIGHT REDUCTION; WOUND DEHISCENCE;

GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; ISOANTIBODIES; OBESITY; PREVALENCE; TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY;

EID: 84879839062     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182869d2f     Document Type: Review

References (141)

1. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing worldVa growing challenge. N Engl J Med 2007; 356: 213.
2. Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012; 307: 491.
3. Ogden CL, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA 2012; 307: 483.
4. Friedman AN, Miskulin DC, Rosenberg IH, et al. Demographics and trends in overweight and obesity in patients at time of kidney transplantation. Am J Kidney Dis 2003; 41: 480.
5. Thuluvath PJ, Guidinger MK, Fung JJ, et al. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010; 10(4 Pt 2): 1003.
6. Russo MJ, Hong KN, Davies RR, et al. The effect of body mass index on survival following heart transplantation: do outcomes support consensus guidelines? Ann Surg 2010; 251: 144.
7. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793.
8. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010; 72: 219.
9. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011; 29: 415.
10. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761.
11. Erridge C, Attina T, Spickett CM, et al. A high-fat meal induces lowgrade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 2007; 86: 1286.
12. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and betacell dysfunction. Eur J Clin Invest 2002; 32(Suppl 3): 14.
13. Shi H, Kokoeva MV, Inouye K, et al. TLR4 links innate immunity and fatty acidYinduced insulin resistance. J Clin Invest 2006; 116: 3015.
14. Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306: 457.
15. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010; 140: 900.
16. Nakamura T, Furuhashi M, Li P, et al. Double-stranded RNAdependent protein kinase links pathogen sensing with stress and metabolic homeostasis. Cell 2010; 140: 338.
17. Boura-Halfon S, Zick Y. Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab 2009; 296: E581.
18. Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116: 1494.
19. Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest 2011; 121: 2126.
20. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772.
21. Starr ME, Evers BM, Saito H. Age-associated increase in cytokine production during systemic inflammation: adipose tissue as a major source of IL-6. J Gerontol A Biol Sci Med Sci 2009; 64: 723.
22. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adiposespecific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79.
23. Okamoto Y, Christen T, Shimizu K, et al. Adiponectin inhibits allograft rejection in murine cardiac transplantation. Transplantation 2009; 88: 879.
24. Wolf AM, Wolf D, Rumpold H, et al. Adiponectin induces the antiinflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 2004; 323: 630.
25. Shibata R, Sato K, Pimentel DR, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX- 2-dependent mechanisms. Nat Med 2005; 11: 1096.
26. Yamaguchi N, Argueta JGM, Masuhiro Y, et al. Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett 2005; 579: 6821.
27. Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000; 96: 1723.
28. Yokota T, Meka CSR, Kouro T, et al. Adiponectin, a fat cell product, influences the earliest lymphocyte precursors in bone marrow cultures by activation of the cyclooxygenase-prostaglandin pathway in stromal cells. J Immunol 2003; 171: 5091.
29. Zhang F, Basinski MB, Beals JM, et al. Crystal structure of the obese protein leptin-E100. Nature 1997; 387: 206.
30. La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol 2004; 4: 371.
31. Sierra-Honigmann MR, Nath AK, Murakami C, et al. Biological action of leptin as an angiogenic factor. Science 1998; 281: 1683.
32. Bennett BD, Solar GP, Yuan JQ, et al. A role for leptin and its cognate receptor in hematopoiesis. Curr Biol 1996; 6: 1170.
33. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing worldVa growing challenge. N Engl J Med 2007; 356: 213.
34. Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012; 307: 491.
35. Ogden CL, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA 2012; 307: 483.
36. Friedman AN, Miskulin DC, Rosenberg IH, et al. Demographics and trends in overweight and obesity in patients at time of kidney transplantation. Am J Kidney Dis 2003; 41: 480.
37. Thuluvath PJ, Guidinger MK, Fung JJ, et al. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010; 10(4 Pt 2): 1003.
38. Russo MJ, Hong KN, Davies RR, et al. The effect of body mass index on survival following heart transplantation: do outcomes support consensus guidelines? Ann Surg 2010; 251: 144.
39. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793.
40. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010; 72: 219.
41. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011; 29: 415.
42. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761.
43. Erridge C, Attina T, Spickett CM, et al. A high-fat meal induces lowgrade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 2007; 86: 1286.
44. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and betacell dysfunction. Eur J Clin Invest 2002; 32(Suppl 3): 14.
45. Shi H, Kokoeva MV, Inouye K, et al. TLR4 links innate immunity and fatty acidYinduced insulin resistance. J Clin Invest 2006; 116: 3015.
46. Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306: 457.
47. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010; 140: 900.
48. Nakamura T, Furuhashi M, Li P, et al. Double-stranded RNAdependent protein kinase links pathogen sensing with stress and metabolic homeostasis. Cell 2010; 140: 338.
49. Boura-Halfon S, Zick Y. Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab 2009; 296: E581.
50. Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116: 1494.
51. Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest 2011; 121: 2126.
52. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772.
53. Starr ME, Evers BM, Saito H. Age-associated increase in cytokine production during systemic inflammation: adipose tissue as a major source of IL-6. J Gerontol A Biol Sci Med Sci 2009; 64: 723.
54. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adiposespecific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79.
55. Okamoto Y, Christen T, Shimizu K, et al. Adiponectin inhibits allograft rejection in murine cardiac transplantation. Transplantation 2009; 88: 879.
56. Wolf AM, Wolf D, Rumpold H, et al. Adiponectin induces the antiinflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 2004; 323: 630.
57. Shibata R, Sato K, Pimentel DR, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX- 2-dependent mechanisms. Nat Med 2005; 11: 1096.
58. Yamaguchi N, Argueta JGM, Masuhiro Y, et al. Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett 2005; 579: 6821.
59. Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000; 96: 1723.
60. Yokota T, Meka CSR, Kouro T, et al. Adiponectin, a fat cell product, influences the earliest lymphocyte precursors in bone marrow cultures by activation of the cyclooxygenase-prostaglandin pathway in stromal cells. J Immunol 2003; 171: 5091.
61. Zhang F, Basinski MB, Beals JM, et al. Crystal structure of the obese protein leptin-E100. Nature 1997; 387: 206.
62. La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol 2004; 4: 371.
63. Sierra-Honigmann MR, Nath AK, Murakami C, et al. Biological action of leptin as an angiogenic factor. Science 1998; 281: 1683.
64. Bennett BD, Solar GP, Yuan JQ, et al. A role for leptin and its cognate receptor in hematopoiesis. Curr Biol 1996; 6: 1170.
65. Sánchez-Margalet V, Martín-Romero C, Santos-Alvarez J, et al. Role of leptin as an immunomodulator of blood mononuclear cells: mechanisms of action. Clin Exp Immunol 2003; 133: 11.
66. Lord GM, Matarese G, Howard JK, et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998; 394: 897.
67. Howard JK, Lord GM, Matarese G, et al. Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob/ob mice. J Clin Invest 1999; 104: 1051.
68. Zarkesh-Esfahani H, Pockley G, Metcalfe RA, et al. High-dose leptin activates human leukocytes via receptor expression on monocytes. J Immunol 2001; 167: 4593.
69. Mancuso P, Gottschalk A, Phare SM, et al. Leptin-deficient mice exhibit impaired host defense in Gram-negative pneumonia. J Immunol 2002; 168: 4018.
70. Caldefie-Chezet F, Poulin A, Tridon A, et al. Leptin: a potential regulator of polymorphonuclear neutrophil bactericidal action? J Leukoc Biol 2001; 69: 414.
71. Tian Z, Sun R, Wei H, et al. Impaired natural killer (NK) cell activity in leptin receptor deficient mice: leptin as a critical regulator in NK cell development and activation. Biochem Biophys Res Commun 2002; 298: 297.
72. Wolf G, Chen S, Han DC, et al. Leptin and renal disease. Am J Kidney Dis 2002; 39: 1.
73. Wu Y, Liu Z, Xiang Z, et al. Obesity-related glomerulopathy: insights from gene expression profiles of the glomeruli derived from renal biopsy samples. Endocrinology 2006; 147: 44.
74. Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol 2009; 51: 212.
75. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005; 11: 183.
76. Feinstein R, Kanety H, Papa MZ, et al. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 1993; 268: 26055.
77. Ehses JA, Perren A, Eppler E, et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 2007; 56: 2356.
78. Giannoukakis N, Rudert WA, Trucco M, et al. Protection of human islets from the effects of interleukin-1beta by adenoviral gene transfer of an Ikappa B repressor. J Biol Chem 2000; 275: 36509.
79. Schäffler A, Müller-Ladner U, Schölmerich J, et al. Role of adipose tissue as an inflammatory organ in human diseases. Endocr Rev 2006; 27: 449.
80. Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem2002; 277: 25863.
81. Kawano T, Saito T, Yasu T, et al. Close association of hypoadiponectinemia with arteriosclerosis obliterans and ischemic heart disease. Metabolism 2005; 54: 653.
82. Maahs DM, Ogden LG, Kinney GL, et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 2005; 111: 747.
83. Tabas I. The role of endoplasmic reticulum stress in the progression of atherosclerosis. Circ Res 2010; 107: 839.
84. Taleb S, Herbin O, Ait-Oufella H, et al. Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 2691.
85. Humar A, Ramcharan T, Denny R, et al. Are wound complications after a kidney transplant more common with modern immunosuppression? Transplantation 2001; 72: 1920.
86. Singh D, Lawen J, AlkhudairW. Does pretransplant obesity affect the outcome in kidney transplant recipients? Transplant Proc 2005; 37: 717.
87. Halme L, Eklund B, Kyllönen L, et al. Is obesity still a risk factor in renal transplantation? Transpl Int 1997; 10: 284.
88. Meier-Kriesche H-U, Arndorfer JA, Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation 2002; 73: 70.
89. Blümke M, Keller E, Eble F, et al. Obesity in kidney transplant patients as a risk factor. Transplant Proc 1993; 25: 2618.
90. Drafts HH, Anjum MR, Wynn JJ, et al. The impact of pre-transplant obesity on renal transplant outcomes. Clin Transplant 1997; 11(5 Pt 2): 493.
91. Pirsch JD, Armbrust MJ, Knechtle SJ, et al. Obesity as a risk factor following renal transplantation. Transplantation 1995; 59: 631.
92. Sampaio MS, Reddy PN, Kuo H-T, et al. Obesity was associated with inferior outcomes in simultaneous pancreas kidney transplant. Transplantation 2010; 89: 1117.
93. Howard RJ, Thai VB, Patton PR, et al. Obese kidney transplant recipients have good outcomes. Transplant Proc 2001; 33: 3420.
94. Yamamoto S, Hanley E, Hahn AB, et al. The impact of obesity in renal transplantation: an analysis of paired cadaver kidneys. Clin Transplant 2002; 16: 252.
95. Doshi MD, Garg N, Reese PP, et al. Recipient risk factors associated with delayed graft function: a paired kidney analysis. Transplantation 2011; 91: 666.
96. Gore JL, Pham PT, Danovitch GM, et al. Obesity and outcome following renal transplantation. Am J Transplant 2006; 6: 357.
97. Johnson DW, Isbel NM, Brown AM, et al. The effect of obesity on renal transplant outcomes. Transplantation 2002; 74: 675.
98. Cacciola RAS, Pujar K, Ilham MA, et al. Effect of degree of obesity on renal transplant outcome. Transplant Proc 2008; 40: 3408.
99. Aker S, Ivens K, Grabensee B, et al. Cardiovascular risk factors and diseases after renal transplantation. Int Urol Nephrol 1998; 30: 777.
100. Modlin CS, Flechner SM, Goormastic M, et al. Should obese patients lose weight before receiving a kidney transplant? Transplantation 1997; 64: 599.
101. Gill IS, Hodge EE, Novick AC, et al. Impact of obesity on renal transplantation. Transplant Proc 1993; 25(1 Pt 2): 1047.
102. Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178.
103. Parikh CR, Klem P, Wong C, et al. Obesity as an independent predictor of posttransplant diabetes mellitus. Transplant Proc 2003; 35: 2922.
104. Carvalho MF, Soares V. Hyperlipidemia as a risk factor of renal allograft function impairment. Clin Transplant 2001; 15: 48.
105. First MR, Neylan JF, Rocher LL, et al. Hypertension after renal transplantation. J Am Soc Nephrol 1994; 4(8 Suppl): S30.
106. Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis 2004; 43: 1071.
107. Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2007; 2: 550.
108. Bosma RJ, Krikken JA, Homan van der Heide JJ, et al. Obesity and renal hemodynamics. Contrib Nephrol 2006; 151: 184.
109. Praga M, Morales E. Obesity, proteinuria and progression of renal failure. Curr Opin Nephrol Hypertens 2006; 15: 481.
110. Schaeffer DF, Yoshida EM, Buczkowski AK, et al. Surgical morbidity in severely obese liver transplant recipientsVa single Canadian Centre Experience. Ann Hepatol 2009; 8: 38.
111. Nair S, CohenDB, CohenMP, et al. Postoperative morbidity, mortality, costs, and long-term survival in severely obese patients undergoing orthotopic liver transplantation. Am J Gastroenterol 2001; 96: 842.
112. Dick AAS, Spitzer AL, Seifert CF, et al. Liver transplantation at the extremes of the body mass index. Liver Transpl 2009; 15: 968.
113. Hillingsø JG, Wettergren A, Hyoudo M, et al. Obesity increases mortality in liver transplantationVthe Danish experience. Transpl Int 2005; 18: 1231.
114. Sawyer RG, Pelletier SJ, Pruett TL. Increased early morbidity and mortality with acceptable long-term function in severely obese patients undergoing liver transplantation. Clin Transplant 1999; 13(1 Pt 2): 126.
115. Boin IFSF, Almeida LV, Udo EY, et al. Survival analysis of obese patients undergoing liver transplantation. Transplant Proc 2007; 39: 3225.
116. Leonard J, Heimbach JK, Malinchoc M, et al. The impact of obesity on long-term outcomes in liver transplant recipientsVresults of the NIDDK liver transplant database. Am J Transplant 2008; 8: 667.
117. Weiss ES, Allen JG, Russell SD, et al. Impact of recipient body mass index on organ allocation and mortality in orthotopic heart transplantation. J Heart Lung Transplant 2009; 28: 1150.
118. Macha M, Molina EJ, Franco M, et al. Pre-transplant obesity in heart transplantation: are there predictors of worse outcomes? Scand Cardiovasc J 2009; 43: 304.
119. Lederer DJ, Wilt JS, D'Ovidio F, et al. Obesity and underweight are associated with an increased risk of death after lung transplantation. Am J Respir Crit Care Med 2009; 180: 887.
120. Allen JG, Arnaoutakis GJ, Weiss ES, et al. The impact of recipient body mass index on survival after lung transplantation. J Heart Lung Transplant 2010; 29: 1026.
121. Hanish SI, Petersen RP, Collins BH, et al. Obesity predicts increased overall complications following pancreas transplantation. Transplant Proc 2005; 37: 3564.
122. Afaneh C, Rich B, Aull MJ, et al. Pancreas transplantation considering the spectrum of body mass indices. Clin Transplant 2009; 25: E520.
123. Humar A, Ramcharan T, Kandaswamy R, et al. Technical failures after pancreas transplants: why grafts fail and the risk factorsVa multivariate analysis. Transplantation 2004; 78: 1188.
124. Glanton CW, Kao T-C, Cruess D, et al. Impact of renal transplantation on survival in end-stage renal disease patients with elevated body mass index. Kidney Int 2003; 63: 647.
125. Pelletier SJ, Schaubel DE, Wei G, et al. Effect of body mass index on the survival benefit of liver transplantation. Liver Transpl 2007; 13: 1678.
126. Segev DL, Simpkins CE, Thompson RE, et al. Obesity impacts access to kidney transplantation. J Am Soc Nephrol 2008; 19: 349.
127. Segev DL, Thompson RE, Locke JE, et al. Prolonged waiting times for liver transplantation in obese patients. Ann Surg 2008; 248: 863.
128. MacLaughlin HL, Cook SA, Kariyawasam D, et al. Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up. Am J Kidney Dis 2010; 55: 69.
129. Cassiman D, Roelants M, Vandenplas G, et al. Orlistat treatment is safe in overweight and obese liver transplant recipients: a prospective, open label trial. Transpl Int 2006; 19: 1000.
130. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292: 1724.
131. Maggard MA, Shugarman LR, Suttorp M, et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med 2005; 142: 547.
132. Modanlou KA, Muthyala U, Xiao H, et al. Bariatric surgery among kidney transplant candidates and recipients: analysis of the United States renal data system and literature review. Transplantation 2009; 87: 1167.
133. Rogers CC, Alloway RR, Alexander JW, et al. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. Clin Transplant 2008; 22: 281.
134. Takata MC, Campos GM, Ciovica R, et al. Laparoscopic bariatric surgery improves candidacy in morbidly obese patients awaiting transplantation. Surg Obes Relat Dis 2008; 4: 159.
135. Molina A, Vendrell J, Gutiérrez C, et al. Insulin resistance, leptin and TNF-alpha system in morbidly obese women after gastric bypass. Obes Surg 2003; 13: 615.
136. Vendrell J, Broch M, Vilarrasa N, et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 2004; 12: 962.
137. Faraj M, Jones P, Sniderman AD, et al. Enhanced dietary fat clearance in postobese women. J Lipid Res 2001; 42: 571.
138. Falkén Y, Hellström PM, Holst JJ, et al. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab 2011; 96: 2227.
139. Michalakis K, Le Roux C. Gut hormones and leptin: impact on energy control and changes after bariatric surgeryVwhat the future holds. Obes Surg 2012; 22: 1648.
140. Miller AD, Smith KM. Medication and nutrient administration considerations after bariatric surgery. Am J Health Syst Pharm 2006; 63: 1852.
141. Marterre WF, Hariharan S, First MR, et al. Gastric bypass in morbidly obese kidney transplant recipients. Clin Transplant 1996; 10: 414.